LEGN
Legend Biotech Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow -10.0% ·
net new positions +20.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +12 | 61.78M | $1.78B | +17 | −5 |
| Q1 2026 | 82 | -3 | 51.41M | $929.52M | +5 | −8 |
| Q4 2025 | 86 | +2 | 50.21M | $1.09B | +2 | n/a |
| Q3 2025 | 13 | -2 | 38.53M | $1.26B | n/a | −2 |
| Q2 2025 | 12 | -1 | 34.51M | $1.22B | +1 | −2 |
| Q1 2025 | 10 | 0 | 13.38M | $453.85M | n/a | n/a |
| Q4 2024 | 10 | -1 | 15.80M | $514.13M | n/a | −1 |
| Q3 2024 | 10 | +3 | 16.52M | $804.74M | +3 | n/a |
| Q2 2024 | 7 | n/a | 18.35M | $812.58M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 11.17M | -2.8% | $544.10M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 2.04M | -27.5% | $99.23M | 0.0% | ▼ Trim | 2 | SEC ↗ ×7 |
| 3 | Citadel Advisors ✦ | 1.32M | -8.9% | $64.16M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 570.38K | -65.6% | $27.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 494.37K | New | $24.09M | 0.0% | New | 1 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (passive) | 494.86K | +3.6% | $23.93M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 195.37K | -35.8% | $9.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Bridgewater Associates ✦ | 165.97K | +0.3% | $8.09M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 60.50K | New | $2.95M | 0.0% | New | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 18.10K | New | $882,013 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $24.09M | 0.0% |
| Two Sigma Investments | $2.95M | 0.0% |
| Renaissance Technologies | $882,013 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 189 holders, 95.78M shares, $1.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 27.37K sh · $258,920
Officer · 5.43K sh · $49,630
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology